Corline Biomedical AB

OM:CLBIO Stock Report

Market Cap: SEK 186.5m

Corline Biomedical Future Growth

Future criteria checks 5/6

Corline Biomedical is forecast to grow earnings and revenue by 114.7% and 46% per annum respectively. EPS is expected to grow by 114.8% per annum. Return on equity is forecast to be 19.1% in 3 years.

Key information

114.7%

Earnings growth rate

114.8%

EPS growth rate

Pharmaceuticals earnings growth75.2%
Revenue growth rate46.0%
Future return on equity19.1%
Analyst coverage

Low

Last updated08 Nov 2024

Recent future growth updates

Recent updates

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Aug 24
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Nov 26
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Jun 22
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Feb 16
We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Jun 14
Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Feb 28
Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Earnings and Revenue Growth Forecasts

OM:CLBIO - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026442817251
12/31/2025301911191
12/31/20249-1-10-21
9/30/202424-10-100N/A
6/30/202429-6-92N/A
3/31/202431-4-37N/A
12/31/202336-2-101N/A
9/30/202337-1-12-2N/A
6/30/2023401-120N/A
3/31/2023384-16-5N/A
12/31/2022332-15-6N/A
9/30/2022311-14-2N/A
6/30/202223-3-15-6N/A
3/31/202219-6-16-6N/A
12/31/202117-7-14-5N/A
9/30/202115-6-12-6N/A
6/30/202113-6-12-7N/A
3/31/202114-6-12-6N/A
12/31/202015-7-14-5N/A
9/30/202014-9-20-7N/A
6/30/202014-9-20-9N/A
3/31/202014-9-20-11N/A
12/31/201912-10-19-14N/A
9/30/201911-9-17-17N/A
6/30/201911-9-5-5N/A
3/31/201910-8-5-4N/A
12/31/201810-7-5-4N/A
9/30/201817-7-8-6N/A
6/30/201816-6N/A-15N/A
3/31/201815-7N/A-16N/A
12/31/201716-8N/A-5N/A
9/30/20177-8N/A-2N/A
6/30/20179-8N/A-2N/A
3/31/201710-6N/A1N/A
12/31/20169-5N/A-7N/A
9/30/20168-6N/A-5N/A
6/30/20167-6N/A-4N/A
3/31/20165-7N/A-5N/A
12/31/20154-6N/A-4N/A
12/31/20144-3N/A-2N/A
12/31/20134-2N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: CLBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CLBIO is expected to become profitable in the next 3 years.

Revenue vs Market: CLBIO's revenue (46% per year) is forecast to grow faster than the Swedish market (1.3% per year).

High Growth Revenue: CLBIO's revenue (46% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLBIO's Return on Equity is forecast to be low in 3 years time (19.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corline Biomedical AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonPenser Access